Dr. Ronald Newbold has over 27 years of Business Development and Alliance Management experience leading business teams in negotiating over $1.5 billion in announced pharma/biotech deals.  Prior to joining EDI, Ron served as Senior Vice President and Head of US Business Development & Alliance Management, Otsuka America Pharmaceuticals, Princeton NJ. 

Ron acquired significant experience in external partnering in the Life Sciences field from his previous activities in large Pharma and biotech companies. Ron is a Ph.D. graduate of the University of Rochester. After completing his postdoctoral fellowship in Medicinal Chemistry at Harvard University, Ron joined Merck where he was ultimately responsible for Strategic Research Initiatives.  Following 14 years with Merck, Ron was the senior business development executive at Sentigen Biosciences, Celldex Therapeutics, and Auspex Pharmaceuticals.

Ron joined Pfizer in 2010 to manage a global team of scientists in over 10 countries evaluating and proposing partnerships of scientific value to broaden Pfizer’s early-stage pipeline. Ron was also responsible for starting and leading the Pfizer Seed Fund, created through an evolution of Pfizer’s Incubator. During Ron’s tenure with Pfizer, he served as Board Observer to several companies, as a member of the Neomed Therapeutics Scientific Advisory Board and he remains Vice Chairman of the Licensing and Ventures Group at the University of Virginia.